Precision Skin Cancer Diagnosis: Gene Expression Profiling for Melanoma and cSCC
Credit(s): 1.00 (60 min)
Thursday, October 6, 2022, 6:30 - 7:30 PM MT Tuesday, October 25, 2022 6:00 - 7:00 PM PTThursday, November 10, 2023, 7:30 - 8:30 PM ETWednesday, February 1, 2023, 7:00 - 8:00 PM CT
Physicians – AMA PRA Category 1 Credit(s) ™
Physician Assistants – AAPA Category 1 CME
Nurse Practitioners – contact hour(s) of continuing education
Early detection and appropriate, risk-adjusted treatment is essential to ensure optimal outcomes for patients diagnosed with skin cancers such as melanoma and cutaneous squamous cell carcinoma (cSCC). Unfortunately, diagnosis of these malignancies can be challenging, and many patients are not diagnosed until later stages of disease. Once a patient is diagnosed, determining their risk status is particularly important, as it has major implications for treatment selection. Failure to appropriately assess patient risk can lead to either over or undertreatment, negatively impacting patient outcomes. In recent years, novel gene expression profiling (GEP) technologies designed to aid in diagnosis and risk assessment have emerged for melanoma and cSCC, and many more are in development. Use of these tests can help dermatology clinicians, including nurse practitioners and physician assistants in early identification of patients with high-risk disease who may require a more aggressive treatment approach.
This activity, Precision Skin Cancer Diagnosis: Gene Expression Profiling for Melanoma and cSCC, will review emerging trends in diagnosis and risk stratification for patients with common skin cancers. This will include practical discussion of how to improve diagnosis of melanoma and new strategies to improve risk stratification for melanoma and cSCC.
Jointly provided by the Potomac Center for Medical Education and Rockpointe
This program is supported by an educational grant from Castle Biosciences, Inc.
Clicking Start Activity indicates that you have reviewed the CME/CE information for this activity
Targeted Therapies For Atopic Dermatitis: On the Cusp of a Golden Era
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.